3320 — China Resources Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$30.09bn
- HK$84.09bn
- CNY244.70bn
- 72
- 96
- 55
- 91
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | PRESS | PRESS |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | fx Final | fx Final | fx Final | Final | Final |
Revenue | |||||
Total Revenue | 180,260 | 178,300 | 196,534 | 218,183 | 244,704 |
Cost of Revenue | |||||
Gross Profit | 29,992 | 28,729 | 29,363 | 33,619 | 38,337 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 171,257 | 169,985 | 188,143 | 208,422 | 233,442 |
Operating Profit | 9,003 | 8,315 | 8,391 | 9,761 | 11,262 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 5,854 | 6,294 | 6,978 | 8,361 | 9,880 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,495 | 4,736 | 5,517 | 6,658 | 7,775 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 2,898 | 2,933 | 3,128 | 3,500 | 3,854 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 2,898 | 2,933 | 3,128 | 3,500 | 3,854 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.426 | 0.54 | 0.527 | 0.567 | 0.716 |
Dividends per Share |